Bioxcel Therapeutics, INC. 8-K Filing
Ticker: BTAI · Form: 8-K · Filed: Apr 1, 2026 · CIK: 0001720893
Sentiment: neutral
Filing Stats: 413 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2026-04-01 06:58:25
Key Financial Figures
- $0.001 B — ch registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic
Filing Documents
- tm2610820d1_8k.htm (8-K) — 23KB
- 0001104659-26-038174.txt ( ) — 182KB
- btai-20260401.xsd (EX-101.SCH) — 3KB
- btai-20260401_lab.xml (EX-101.LAB) — 33KB
- btai-20260401_pre.xml (EX-101.PRE) — 22KB
- tm2610820d1_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On April 1, 2026, BioXcel Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI . The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 1, 2026 BIOXCEL THERAPEUTICS, INC. /s/ Richard Steinhart By: Richard Steinhart Title: Chief Financial Officer